Cargando…

Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies

Background: In routine clinical practice, non-standard doses of direct oral anticoagulants (DOACs) are commonly used in patients with atrial fibrillation (AF). However, data on the clinical outcomes of non-standard doses of DOACs are limited. Methods: The MEDLINE, Embase, and Cochrane Library databa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Nan-Nan, Zhang, Chi, Wang, Na, Wang, Jia-Liang, Gu, Zhi-Chun, Han, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012667/ https://www.ncbi.nlm.nih.gov/pubmed/33815125 http://dx.doi.org/10.3389/fphar.2021.645479

Ejemplares similares

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
por: Qian, Jun, et al.
Publicado: (2021)

Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort
por: Rodríguez-Bernal, Clara L., et al.
Publicado: (2017)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
por: Zhao, Nan, et al.
Publicado: (2022)

A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region
por: García-Sempere, Aníbal, et al.
Publicado: (2017)

An Updated Pooled Analysis of Off-Label Under and Over-Dosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation
por: Shen, Nan-Nan, et al.
Publicado: (2023)

Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
por: Perreault, Sylvie, et al.
Publicado: (2022)

Physician–Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development
por: Wang, Na, et al.
Publicado: (2021)

Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation
por: Gustafson, Whitney L., et al.
Publicado: (2019)

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol
por: Holbrook, Anne, et al.
Publicado: (2016)

Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain
por: Hurtado-Navarro, Isabel, et al.
Publicado: (2018)

Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2023)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting
por: Zhang, Jinhua, et al.
Publicado: (2020)

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022)

Real-World Management and Clinical Outcomes of Stroke Survivors With Atrial Fibrillation: A Population-Based Cohort in Spain
por: Rodríguez-Bernal, Clara L., et al.
Publicado: (2021)

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
por: Zhao, Shujuan, et al.
Publicado: (2020)

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world
por: Kozieł, Monika, et al.
Publicado: (2021)

Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting
por: Wu, Yue, et al.
Publicado: (2021)

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
por: Chen, Chiung-Mei, et al.
Publicado: (2022)

Semantic computational analysis of anticoagulation use in atrial fibrillation from real world data
por: Bean, Daniel M., et al.
Publicado: (2019)

Use of Oral Anticoagulation in a Real‐World Population With Device Detected Atrial Fibrillation
por: Kaplan, Rachel M., et al.
Publicado: (2020)

Comparison of effectiveness and safety of direct oral anticoagulants versus vitamin-k antagonists in elderly patients with atrial fibrillation: a systematic review and cost-effectiveness analysis protocol
por: Wang, Na, et al.
Publicado: (2020)

Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Grymonprez, Maxim, et al.
Publicado: (2020)

Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage: A systematic review and meta-analysis
por: Zhou, Qiang, et al.
Publicado: (2023)

Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
por: Pham, Phuong N., et al.
Publicado: (2019)

Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies
por: Zhang, Chi, et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review
por: Acanfora, Domenico, et al.
Publicado: (2019)

Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation
por: Armentaro, Giuseppe, et al.
Publicado: (2023)

Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
por: Roberti, Roberta, et al.
Publicado: (2021)

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials
por: Shen, Nan-Nan, et al.
Publicado: (2020)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
por: Konicki, Robyn, et al.
Publicado: (2020)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?
por: Contractor, Tahmeed, et al.
Publicado: (2011)

Risk of cognitive impairment with non-vitamin K antagonist oral anticoagulants in atrial fibrillation: Protocol for a systemic review of randomized controlled trials and real-world studies
por: Shen, Long, et al.
Publicado: (2018)

Anticoagulation Quality of Warfarin and the Role of Physician–Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study
por: Qiu, Sha, et al.
Publicado: (2021)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019)

Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients
por: Campos-Staffico, Alessandra M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_794fievl4ffqi4gfj676um1des